Cancer
Benaroya Research Institute and Virginia Mason Medical Center conduct cancer clinical trials to find better ways to treat and prevent cancer. Our studies include the use of chemotherapy, radiation, and targeted therapies, as well as contributing to the development of diagnostic tests and improving quality of life/symptom management. More than 100 cancer-related clinical studies are conducted at Virginia Mason Medical Center each year, including studies sponsored by the National Cancer Institute and industry-sponsored trials.
Clinical Research Studies in Cancer
We have ongoing clinical research studies in several areas of cancer research. Studies labeled as “Enrolling” are actively accepting new participants while studies labeled as “Closed to Enrollment” are still active but no longer seeking new participants.
Please email Cancer Clinical Research or call (206) 287-6270 for more information.
- Bladder Cancer
MODERN: AN INTEGRATED PHASE 2/3 AND PHASE 3 TRIAL OF MRD-BASED OPTIMIZATION OF ADJUVANT THERAPY IN UROTHELIAL CANCER
Principal Investigator: Huong Pham, MD
Status: Enrolling
A Randomized Phase III Trial of Intravesical BCG versus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
Principal Investigator: Huong Pham, MD
Status: EnrollingAdjuvant study of MK-3475 (Pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma (Ambassador) versus observation.
Principal Investigator: Huong Pham, MD
Status: Closed to EnrollmentA phase 2, randomised, multi-centre, open label trial to evaluate safety & efficacy of intravesical nadofaragene firadenovec alone or in combo with chemo (gem & doce) or immunotherapy (pembro) in high-grade BCG unresponsive NMIBC
Principal Investigator: JJ Zhang, MD
Status: Not Yet Enrolling- Blood Cancer
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
Principal Investigator: David Aboulafia, MD
Status: EnrollingA Randomized, Open-label, Phase 3 Trial of A+AVD versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma
Principal Investigator: David Aboulafia, MD
Status: Closed to EnrollmentSWOG S0016 A Phase III Trial of CHOP Plus Rituximab versus CHOP Plus Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for the Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphoma
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment- Brain Cancer
A Multicenter Observational Study of GammaTile™ Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms Short Title: STaRT
Principal Investigator: Huong Pham, MD
Status: EnrollingLomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in MGMT+ GBM
Principal Investigator: John Paul Flores, MD
Status: EnrollingA Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) versus Surgically Targeted Radiation Therapy (STaRT) with Gamma Tile for Treatment of Newly Diagnosed Metastatic Brain Tumors.
Principal Investigator: Huong Pham, MDStatus: Closed to Enrollment
- Breast Cancer
NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemo to Ovarian Function Suppression + Endocrine Therapy in Premenopausal Patients w/ pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)
Principal Investigator: Huong Pham, MD
Status: EnrollingElacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
Principal Investigator: Nanette Robinson, MD
Status: Enrolling- Cancer Non-Specific
A Phase 1/2a, Open-Label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutated Solid Tumors (VS-7375-101)
Principal Investigator: Vincent Picozzi, MD
Status: EnrollingEA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III TrialEA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
Principal Investigator: Bruce Lin, MD
Status: EnrollingVirginia Mason Medical Center and Benaroya Research Institute Tumor Tissue Repository (VM-BRITE) Sample Collection Protocol
Principal Investigator: Christopher Gault, MD
Status: EnrollingA prospective observational cohort study to assess miRNA 371 for outcome prediction in patients with newly diagnosed germ cell tumors
Principal Investigator: John Paul Flores, MD
Status: Closed to Enrollment- Colorectal Cancer
A PHASE 3 RANDOMIZED TRIAL OF NEOADJUVANT CHEMOTHERAPY, EXCISION AND OBSERVATION VERSUS CHEMORADIOTHERAPY FOR EARLY RECTAL CANCER
Principal Investigator: Huong Pham, MD
Status: EnrollingA multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection
Principal Investigator: Bruce Lin, MD
Status: EnrollingHAI Consortium Research Network: Registry of Hepatic Arterial Infusion (HAI)
Principal Investigator: Lauren Wancata, MD
Status: EnrollingThe Janus Rectal Cancer Trial: A Randomized Phase II/III Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy Regarding Clinical Complete Response and Disease-free Survival in Patients with Locally Advanced Rectal Cancer
Principal Investigator: Val Simianu, MD
Status: Closed to EnrollmentRandomized trial of standard chemotherapy alone or combined with Atezolizumab as adjuvant therapy for patients with Stage III colon cancer and deficient DNA mismatch repair.
Principal Investigator: Bruce Lin, MD
Status: Closed to EnrollmentA Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III –Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Principal Investigator: Bruce Lin, MD
Status: Closed to EnrollmentA Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation
Principal Investigator: Bruce Lin, MD
Status: Closed to EnrollmentANCHOR: Anal Cancer/HSIL Outcomes Research Study
Principal Investigator: David Aboulafia, MD
Status: Closed to Enrollment- Gastroesophageal Cancer
A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors
Principal Investigator: Bruce Lin, MD
Status: Closed to Enrollment- Hepatobiliary Cancer (Liver and Biliary Tract)
A PHASE II, OPEN-LABEL, MULTI-COHORT, MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS
Principal Investigator: Bruce Lin, MD
Status: EnrollingA Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Principal Investigator: Bruce Lin, MD
Status: EnrollingALTUS: PERFORMANCE OF A MULTI-TARGET HEPATOCELLULAR CARCINOMA (HCC) TEST IN SUBJECTS WITH INCREASED RISK
Principal Investigator: Asma Siddique, MD
Status: EnrollingA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS (AMBER)
Principal Investigator: Bruce Lin, MD
Status: Closed to EnrollmentA Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen
Principal Investigator: Bruce Lin, MD
Status: Closed to EnrollmentA PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA
Principal Investigator: Bruce Lin, MD
Status: Closed to EnrollmentA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)
Principal Investigator: Bruce Lin, MD
Status: Closed to Enrollment- HIV/AIDS Malignancies
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living with HIV: A Feasibility Study
Principal Investigator: David Aboulafia, MD
Status: EnrollingUse of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AIDS Malignancy Consortium
Principal Investigator: David Aboulafia, MD
Status: Closed to EnrollmentClinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma
Principal Investigator: David Aboulafia, MD
Status: Closed to EnrollmentA Phase I Study of Ipilimumab and Nivolumab in Advanced HIV-Associated Solid Tumors with Expansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
Principal Investigator: David Aboulafia, MD
Status: Closed to EnrollmentANCHOR: Anal Cancer/HSIL Outcomes Research Study
Principal Investigator: David Aboulafia, MD
Status: Closed to Enrollment- Kaposi Sarcoma
A Phase 2 Trial of Ixazomib for Kaposi Sarcoma
Principal Investigator: David Aboulafia, MD
Status: EnrollingMulticenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma
Principal Investigator: David Aboulafia, MD
Status: Closed to EnrollmentA Phase II Study of sEphB4-HAS in Kaposi Sarcoma
Principal Investigator: David Aboulafia, MD
Status: Closed to EnrollmentA Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma: A Trial of the AIDS Malignancy Consortium (AMC)
Principal Investigator: David Aboulafia, MD
Status: Closed to Enrollment- Kidney Cancer
NRG-GU012: RANDOMIZED PHASE II STEREOTACTIC ABLATIVE RADIATION THERAPY (SABR) FOR METASTATIC UNRESECTED RENAL CELL CARCINOMA (RCC) RECEIVING IMMUNOTHERAPY (SAMURAI)
Principal Investigator: Huong Pham, MD
Status: Enrolling- Neuroendocrine Tumors
Randomized, double-blinded phase III study of cabozantinib versus placebo in patients with advanced neuroendocrine tumors after progression on everolimus (CABINET)
Principal Investigator: Bruce Lin, MD
Status: Closed to EnrollmentAn International, Non-Interventional, Post-Authorization Long-Term Safety Study of Lutathera®, in Patients with Unresectable or Metastatic, Well-Differentiated, Somatostatin Receptor Positive, Gastroenteropancreatic Neuroendocrine Tumours (SALUS study).
Principal Investigator: Bruce Lin, MD
Status: Closed to Enrollment- Pancreatic Cancer
A Phase Ib Dose Escalation/Dose Expansion Study of PTM-101 as an Adjunct to Neoadjuvant Therapy for Treatment Naïve, Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Principal Investigator: Vincent Picozzi, MD
Status: EnrollingA Phase 1 Open-label Study to Assess the Safety and Tolerability of Zolbetuximab (IMAB362) in Combination with Chemotherapy (mFOLFIRINOX) in Participants with CLDN18.2 Positive Metastatic Pancreatic Adenocarcinoma
Principal Investigator: Vincent Picozzi, MD
Status: EnrollingA Phase 1b Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ATP150/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in Patients with KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma
Principal Investigator: Vincent Picozzi, MD
Status: EnrollingA Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
Principal Investigator: Vincent Picozzi, MD
Status: EnrollingAnalysis of Health Outcome of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer
Principal Investigator: Vincent Picozzi, MD
Status: EnrollingA Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma
Principal Investigator: Vincent Picozzi, MD
Status: Closed to EnrollmentA Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with Avutometinib (VS-6766) and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas
Principal Investigator: Vincent Picozzi, MD
Status: Closed to EnrollmentA Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Ampligen® Compared to Control Group / No Treatment Following FOLFIRINOX in Subjects with Locally Advanced Pancreatic Adenocarcinoma
Principal Investigator: Vincent Picozzi, MD
Status: Closed to EnrollmentA Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
Principal Investigator: Vincent Picozzi, MD
Status: Closed to EnrollmentA Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors
Principal Investigator: Vincent Picozzi, MD
Status: EnrollingVM-BRI repository for early detection of pancreas cancer (VM-BRIDPAN)
Principal Investigator: Margaret Mandelson, PhD
Status: Closed to EnrollmentAlternating neoadjuvant Gemcitabine-Nab-Paclitaxel and nal-IRI with 5-Fluorouracil and folinic acid (Leucovorin) regimens in resectable and borderline resectable pancreatic cancer, A Pilot Study
Principal Investigator: Vincent Picozzi, MD
Status: Closed to Enrollment- Prostate Cancer
NRG-GU009: PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*)
Principal Investigator: Huong Pham, MD and John Paul Flores, MD
Status: EnrollingNRG-GU010: PARALLEL PHASE III RANDOMIZED TRIALS OF GENOMIC-RISK STRATIFIED UNFAVORABLE INTERMEDIATE RISK PROSTATE CANCER: DE-INTENSIFICATION AND INTENSIFICATION CLINICAL TRIAL EVALUATION (GUIDANCE)
Principal Investigator: Huong Pham, MD and John Paul Flores, MD
Status: EnrollingA Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Principal Investigator: John Paul Flores, MD
Status: Closed to EnrollmentPhase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for localized intermediate risk prostate cancer
Principal Investigator: Huong Pham, MD
Status: Closed to EnrollmentA Multicenter, Randomized, Double-Blind, Placebo-Controlled,Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Principal Investigator: Joseph Rosales, MD
Status: Closed to Enrollment
Cancer Clinical Research Team Leaders
Rachel Dowty, RN, MPH
Kara Turner
Cancer Clinical Research Team Members
Hannah Butterklee
Sonja Duncan
Marie Hwang
Priscilla Kim
Angie Moua
Meredith Pellon
Kelly Quinn
Karolina Rauch
Rene Rodriguez
Nasira Sharma
Colleen Soleau
